XML 48 R35.htm IDEA: XBRL DOCUMENT v3.25.2
Summary of Significant Accounting Policies - Additional Information (Detail)
 12 Months Ended
Dec. 31, 2024
USD ($)
Segment
$ / shares
shares
Dec. 31, 2023
USD ($)
shares
Summary Of Significant Accounting Policies [Line Items]    
Cash, cash equivalents and restricted cash, maturity period three months or less  
Number of operating business segments | Segment 1  
Impairments of long-lived assets $ 0 $ 0
Tax benefit $ 0  
Income tax examination, likelihood of settlement, description The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement.  
Income tax examination, likelihood of settlement, percentage 50.00%  
Pre-Funded Warrants [Member]    
Summary Of Significant Accounting Policies [Line Items]    
Basic weighted average shares outstanding | shares 12,443,755 5,776,270
Warrants exercise price | $ / shares $ 0.001  
Accounting Standards Update 2023-07 [Member]    
Summary Of Significant Accounting Policies [Line Items]    
Change in Accounting Principle, Accounting Standards Update, Adopted [true false] true  
Change in Accounting Principle, Accounting Standards Update, Adoption Date Dec. 31, 2024  
Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false] true  
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] true  
Anelixis Therapeutics, LLC and Otic Pharma, Ltd.    
Summary Of Significant Accounting Policies [Line Items]    
Ownership interest percentage 100.00%  
Otic Pharma, Inc. [Member]    
Summary Of Significant Accounting Policies [Line Items]    
Ownership interest percentage 100.00%